[Funding alert] UK-based InvenireX Secures £500k in Funding
Mar 19, 2024 | By Oliver Bennett

InvenireX, biotech company advancing PCR laboratory tests Secures £500k in funding. XTX Ventures and DSW Ventures were among the backers.
The money will be used by the company to refine the finished product and send it to outside research and development facilities for additional technical verification.
Read also - Baden-based Crosstown H2R Secures over €2 Million in Funding
Daniel Todd founded InvenireX in 2021 while pursuing a PhD in DNA and nanotechnology at the University of Newcastle. With the help of programmable DNA, or "nanites," and artificial intelligence, the company has created a platform that enables scientists to quickly test raw materials for biomarkers at minuscule concentrations without the need for pre-processing.
RECOMMENDED FOR YOU
NextSTEP funding news – Milan-based NextSTEP Invests €590k in Five Cleantech Startup
Kailee Rainse
Dec 3, 2024
Commit Biologics Raises €54Mn in Seed Funding to Develop Cancer and Autoimmune Disease Treatments
Oliver Bennett
Nov 17, 2026
FION Energy Raises €1.4M To Expand AI-Powered Industrial Battery Solutions
Kailee Rainse
Dec 10, 2025
It may find extensive use in personalized treatment, environmental monitoring, and early illness diagnosis. Currently, the organization is working with commercial partners on two proof-of-concept projects related to cancer detection and agriculture.
Read also - Munich-based VC Alpine Space Ventures Secures €10 Million in Funding
About InvenireX
To enable their scientists to speed life sciences research, InvenireX is developing ultra-sensitive, real-time instrumentation for nucleic acid identification that is powered by the most recent object-detection neural networks.






